FGFR2 and cholangiocarcinoma: Futibatinib demonstrated efficacy with durable responses in patients with intrahepatic CCA harboring FGFR2 fusion/rearrangements in the pivotal FOENIX-CCA2 phase 2 study (NCT02052778).